Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BGB-C354 |
| Synonyms | |
| Therapy Description |
BGB-C354 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CD276 (B7-H3) linked to a topoisomerase I inhibitor, which potentially induces cytotoxicity in CD276 (B7-H3)-expressing tumor cells and antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 5731). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BGB-C354 | BGB C354|BGBC354 | CD276 Antibody 21 | BGB-C354 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CD276 (B7-H3) linked to a topoisomerase I inhibitor, which potentially induces cytotoxicity in CD276 (B7-H3)-expressing tumor cells and antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 5731). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06422520 | Phase I | BGB-C354 BGB-C354 + Tislelizumab | A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 1 |